Moving Forward with Purpose: NeoLumina Prepares for Phase 2 Clinical Trial in Binge Eating Disorder

NeoLumina BioScience advances its mission to redefine mental health treatment through science, conviction, and collaboration — preparing to launch a Phase 2 clinical trial targeting one of the most challenging and overlooked disorders.

At NeoLumina BioScience, progress isn’t just about speed — it’s about precision, purpose, and conviction.

As shared by our CEO, Dr. Gaetano Morello, the company has completed its clinical protocol and is preparing to submit to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical trial focused on binge eating disorder — one of the most difficult and under-treated conditions in mental health.

This milestone reflects years of careful, collaborative work grounded in neuroscience, psychiatry, and pharmaceutical innovation. It represents not only scientific advancement but also NeoLumina’s unwavering commitment to address conditions that have long been neglected or misunderstood.

At the same time, NeoLumina is proud to announce a strategic partnership with Catalent, a leading global pharmaceutical organization. Together, we are developing a next-generation psychedelic-based treatment designed to bring real, measurable hope to individuals who have been waiting far too long for new therapeutic options.

“Every step we take matters. Every move brings us closer to making a difference,” says Dr. Morello.

NeoLumina’s journey continues with the same principle that has guided it from the beginning:
when science meets humanity, healing begins.

Watch the full message from our CEO below: